Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Exclusivity For Brand Biologics Added In Senate FOB Provision, But Generics Have $1 Bil. In Leverage From CBO Score

Executive Summary

The roll-out of the health care reform bill now under debate in the Senate is a good news/bad news event for the generic industry
Advertisement

Related Content

Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?
Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?
Follow-On Biologics Politics: AARP's Rother Explains "What Beat Us"
Generics Industry Faces Five Major Challenges, Actavis CEO Says (We're Partly Responsible For One Of Them, He Acknowledges)
Generics Industry Faces Five Major Challenges, Actavis CEO Says (We're Partly Responsible For One Of Them, He Acknowledges)
Teva, Eyeing Follow-Ons For Most Biologics, Starts With Amgen's Neupogen
Follow-On Biologics' Other Pathway: Mechanisms To Resolve Patent Disputes Vary In Legislation
"Interchangeable" Biosimilars Get Same Medicare Code As Innovators In Bill
NORD Refines Orphan Exclusivity Position
Biosimilar Interchangeability Does Not Create Substitution Under House Bills

Topics

Advertisement
UsernamePublicRestriction

Register

PS051713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel